- Went public on NASDAQ (MOTS), Feb 2018
- Raised $30M Series B led by GJG Life Sciences, Feb 2017
- Raised $12M debt round led by Kreos Capital, Jul 2021
About
Motus GI Holdings, Inc. is a medical technology company with subsidiaries in the U.S. and Israel, dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy and upper GI endoscopy. The company's flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device that facilitates the cleaning of a poorly prepared gastrointestinal tract during endoscopy procedures. The Pure-Vu® System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during procedures while preserving established procedural workflow and techniques. The company aims to improve outcomes and lower costs for hospitals by reducing the time to successful procedures, minimizing delayed and incomplete procedures, and improving the quality of an exam.
Funding history · 5 rounds · $76.5M total
Headcount over time
Q&A
- What is Motus GI's primary product?
- Motus GI's flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device designed to clean a poorly prepared gastrointestinal tract during endoscopy procedures, improving visualization.
- When did Motus GI go public?
- Motus GI became a public company on NASDAQ in February 2018.
- What was the amount raised in Motus GI's initial public offering?
- In February 2018, Motus GI raised $17,500,000 through its Public Offering, with.
- Has Motus GI received recent FDA clearances for its products?
- Yes, in October 2023, Motus GI received FDA clearance to commercialize the Pure-Vu EVS Gastro and Gen 4 Colon systems.
- What was a significant debt financing event for Motus GI in 2021?
- In July 2021, Motus GI secured $12,000,000 in.
- What was the outcome of a European study on Motus GI's Pure-Vu System?
- In January 2024, Motus GI Holdings published positive results from a European study demonstrating the second-generation Pure-Vu System's effectiveness in improving visualization for colonoscopy in patients with a history of poor bowel preparation.
- What was Motus GI's most recent funding round?
- Motus GI's most recent funding round was a Public Offering in May 2023, which raised $3,900,000.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | motusgi.com |
|---|---|
| linkedin.com/company/10597881 | |
| facebook.com/MotusGI | |
| YouTube | youtube.com/channel/UCxoy2H9FLs2FfNQljgR8rHA |
Identifiers & details
| Legal name | Motus GI Holdings, Inc. |
|---|---|
| Former names | Booton |
| Founded | 2008 |
| Employees (exact) | 15 |
| Offices | Fort Lauderdale |
| Market cap | $639 |
| Status reason | Public on NASDAQ on Feb, 2018 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2018-02 | NASDAQ | MOTS | $17.5M |
Radar intelligence
Patents
| EPO | 16 |
|---|
Web history (Wayback)
| Domain | motusgi.com |
|---|
Certificate / subdomain footprint
| Subdomains | 6 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514188135 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2008-10-06 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | קרן היסוד 22 טירת כרמל |